Literature DB >> 21317704

Perspectives on pure ovarian stromal neoplasms and tumor-like proliferations of the ovarian stroma.

Lawrence M Roth1, Bernard Czernobilsky.   

Abstract

In this study, we discuss the advances in our knowledge of the pathology of pure ovarian stromal neoplasms and discuss tumor-like conditions of ovarian stroma that can mimic ovarian stromal neoplasms clinically, macroscopically, or histologically. This review emphasizes recent studies and those that have significantly advanced our knowledge in the past. The neoplasms in this group occur over a wide age range and are often unilateral. In difficult cases, immunocytochemistry provides improved diagnostic accuracy. The most useful antibodies in this regard are inhibin and calretinin that are positive in most tumors and tumor-like proliferations in the ovarian stromal category. Steroidogenic factor 1 is a promising new marker that has not yet been completely validated. Recent studies of tumors in the fibroma-thecoma group suggest that nuclear atypia is more significant than mitotic activity in the assessment of the biological behavior of these neoplasms. Wherever applicable, we discuss molecular techniques that are currently diagnostically useful.

Entities:  

Mesh:

Year:  2011        PMID: 21317704     DOI: 10.1097/PAS.0b013e31820acb89

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

1.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

2.  Gorlin syndrome presenting with a unilateral ovarian fibroma in a 22-year-old woman: a case report.

Authors:  Terence Finch; Chitra Pushpanathan; Krista Brown; Yasser El-Gohary
Journal:  J Med Case Rep       Date:  2012-06-12

3.  Case report of bilateral ovarian fibromas associated with de novo germline variants in PTCH1 and SMARCA4.

Authors:  Tomoyasu Higashimoto; Christy Haakonsen Smith; Mark R Hopkins; John Gross; Deyin Xing; Jae W Lee; Traevia Morris; Joann Bodurtha
Journal:  Mol Genet Genomic Med       Date:  2022-06-30       Impact factor: 2.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.